Diamond, Eli L.

Publications

Sort by

Co-Author Network

selected publications

Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. Clinical nuclear medicine. 2020 Academic Article GET IT
Times cited: 22
The unique burden of rare cancer caregiving: caregivers of patients with Erdheim-Chester disease. Leukemia & lymphoma. 2020 Academic Article GET IT
Times cited: 8
Pan-Cancer Efficacy of Vemurafenib in BRAF ^V600-Mutant Non-Melanoma Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 97
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature medicine. 2019 Academic Article GET IT
Times cited: 137
Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 107
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1. Haematologica. 2019 Article GET IT
Times cited: 41
Sequencing and curation strategies for identifying candidate glioblastoma treatments. BMC medical genomics. 2019 Academic Article GET IT
Times cited: 7
Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular cancer therapeutics. 2019 Academic Article GET IT
Times cited: 25
A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease. Blood advances. 2019 Academic Article GET IT
Times cited: 18
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Academic Article GET IT
Times cited: 240
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 36
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA oncology. 2018 Academic Article GET IT
Times cited: 286
Single-agent dabrafenib for BRAF^V600E-mutated histiocytosis. Haematologica. 2018 Academic Article GET IT
Times cited: 37
Associations between Mild Cognitive Dysfunction and End-of-Life Outcomes in Patients with Advanced Cancer. Journal of palliative medicine. 2018 Academic Article GET IT
Times cited: 3
Prognostic awareness and communication preferences among caregivers of patients with malignant glioma. Psycho-oncology. 2017 Academic Article GET IT
Times cited: 33
Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma. Neuro-oncology. 2017 Academic Article GET IT
Times cited: 56
Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatric blood & cancer. 2017 Information Resource GET IT
Times cited: 24
Erdheim-Chester disease: the "targeted" revolution. Blood. 2017 Article GET IT
Times cited: 7
Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric blood & cancer. 2017 Academic Article GET IT
Times cited: 15
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017 Academic Article GET IT
Times cited: 106
Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood. 2017 Academic Article GET IT
Times cited: 94
Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017 Academic Article GET IT
Times cited: 132
Frequency and Risk Factors for Live Discharge from Hospice. Journal of the American Geriatrics Society. 2017 Academic Article GET IT
Times cited: 21
Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016 Academic Article GET IT
Times cited: 52
Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma. Journal of pain and symptom management. 2016 Academic Article GET IT
Times cited: 21
Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood. 2016 Article GET IT
Times cited: 24
Histiocytic neoplasms in the era of personalized genomic medicine. Current opinion in hematology. 2016 Information Resource GET IT
Times cited: 39
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016 Information Resource GET IT
Times cited: 1045
High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system. Leukemia & lymphoma. 2016 Article GET IT
Times cited: 4
Nonenhancing Leptomeningeal Metastases: Imaging Characteristics and Potential Causative Factors. The Neurohospitalist. 2016 Academic Article GET IT
Times cited: 22
Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas. Journal of neuroimaging : official journal of the American Society of Neuroimaging. 2015 Academic Article GET IT
Times cited: 27
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer discovery. 2015 Academic Article GET IT
Times cited: 400
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 1483
Rates and risks for late referral to hospice in patients with primary malignant brain tumors. Neuro-oncology. 2015 Academic Article GET IT
Times cited: 67
Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"?. Acta neuropathologica. 2014 Article GET IT
Times cited: 60
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer discovery. 2014 Academic Article GET IT
Times cited: 116
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014 Academic Article GET IT
Times cited: 202
Prognostic awareness and communication of prognostic information in malignant glioma: a systematic review. Journal of neuro-oncology. 2014 Information Resource GET IT
Times cited: 43
Temporal lobe meningioma with ipsilateral herpes simplex encephalitis. The Neurohospitalist. 2014 Academic Article GET IT
Detection of an NRAS mutation in Erdheim-Chester disease. Blood. 2013 Article GET IT
Times cited: 47
Minor cognitive impairments in cancer patients magnify the effect of caregiver preferences on end-of-life care. Journal of pain and symptom management. 2012 Academic Article GET IT
Times cited: 22
Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease. Neuro-degenerative diseases. 2012 Academic Article GET IT
Times cited: 42
Glioma stem cell signaling: therapeutic opportunities and challenges. Expert review of anticancer therapy. 2010 Information Resource GET IT
Times cited: 34
Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 314
Relationship of fMRI activation to clinical trial memory measures in Alzheimer disease. Neurology. 2007 Academic Article GET IT
Times cited: 36
Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Archives of neurology. 2001 Academic Article GET IT
Times cited: 176

more ...

less ...

Background

education and training

M.D., Albert Einstein College of Medicine of Yeshiva University 2007
M.Phil., University of Cambridge (United Kingdom) 2002
B.A., Harvard University 2001

Contact

full name

Eli L. Diamond

VIVO Weill Cornell Medical College

Eli L. Diamond Associate Professor of Neurology

Publications

selected publications

Background

education and training

Contact

full name